Citations

Showing 10 of 108094 citations.

The Elephant in the Waiting Room: An Urgent Call for Papers to Address the Public Health Crisis of Long COVID
Chakraborty, Rana , Lambert, Natalie , Pinto, Melissa D.

Mayo Clinic

Clinical Nursing Research | October 6, 2022 | Volume: 31 | Issue: 8 | Pages: 1387-1389

10.1177/10547738221132603 | PMID 36200625 Get It

The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms
Thiele, Jürgen, Kvasnicka, Hans Michael , Orazi, Attilio , Gangat, Naseema , Vannucchi, Alessandro M. , Barbui, Tiziano , Arber, Daniel A. , Tefferi, Ayalew , Gangat, Naseema , Vannucchi, Alessandro M , Barbui, Tiziano , Arber, Daniel A , Tefferi, Ayalew , Orazi, Attilio , Gianelli, Umberto

Mayo Clinic

American Journal of Hematology | October 6, 2022 | Volume: 98 | Issue: 1 | Pages: 166-179

10.1002/ajh.26751 | PMID 36200127 Get It

AbstractA group of international experts, including hematopathologists, oncologists, and geneticists were recently summoned (September 2021, Chicago, IL, USA) to update the 2016/17 World Health Organization classification system for hematopoietic tumors. After careful deliberation, the group introduced the new International Consensus Classification (ICC) for Myeloid Neoplasms and Acute Leukemias. This current in‐depth review focuses on the ICC‐2022 category of JAK2 mutation‐prevalent myeloproliferative neoplasms (MPNs): essential thrombocythemia, polycythemia vera, primary myelofibrosis, and MPN, unclassifiable. The ICC MPN subcommittee chose to preserve the primary role of bone marrow morphology in disease classification and diagnostics, while also acknowledging the complementary role of genetic markers for establishing clonality, facilitating MPN subtype designation, and disease prognostication.
Complement complex 1 subunit q‐mediated hepatic stellate cell activation with connective tissue growth factor elevation is a prognostic factor for survival in rat and human chronic liver diseases
Eguchi, Akiko , Iwasa, Motoh , Sugimoto, Ryosuke, Tempaku, Mina, Yoshikawa, Kyoko, Yoshizawa, Naohiko , Povero, Davide , Sugimoto, Kazushi, Takei, Yoshiyuki, Nakagawa, Hayato , Hasegawa, Hiroshi

Mayo Clinic

Hepatology Communications | October 6, 2022 | Volume: 6 | Issue: 12 | Pages: 3515-3527

10.1002/hep4.2097 | PMID 36199236 Get It

Abstract Complement complex 1 subunit q (C1q) has multiple functions, including cell migration, in addition to its traditional complement‐activating effect. Research shows C1q is a ligand for frizzled receptors (FZDs). FZD‐induced yes‐associated protein (YAP)/transcriptional co‐activator with PDZ‐binding motif (TAZ) alternate Wnt signaling activation induces connective tissue growth factor (CTGF) production and hepatic stellate cell (HSC) activation. However, no study exists in which C1q directly induces CTGF in HSCs. Here, we investigated the role of C1q in HSC activation. Human HSCs (LX2) were incubated with C1q to assess HSC activation. C1q and fibrotic markers were assessed using immunohistochemistry, immunoblotting, and quantitative reverse‐transcription polymerase chain reaction in cirrhotic rats administered CCl4 for 21 weeks. Serum C1q, liver function, and fibrosis score were measured in 91 patients with chronic liver disease. The correlations between serum C1q and liver function, fibrosis score, and survival prognosis were examined. C1q‐activated LX2s showed morphologic changes, up‐regulation of CTGF, tissue inhibitors of metalloproteinases (TIMP‐1), and alternate Wnt signal genes FZD2, TAZ, and cysteine‐rich angiogenic inducer 61 (Cyr61). Cirrhotic rat liver C1q expression correlated with the Azan‐positive area and expression of CTGF, TIMP‐1, hyaluronan synthase (HAS)1, HAS3, and CD44. Expression of C1q protein and C1q, CTGF, and TIMP‐1 genes were higher in deceased cirrhotic rat livers compared to surviving rats. Human serum C1q levels increased in liver cirrhosis compared to chronic hepatitis and correlated with liver fibrosis and functional markers. Ten patients suffered liver‐related death over a 66‐month observation period. The C1q cut‐off value (11 mg/dl) showed patients with serum values < 11 mg/dl had longer rates of survival compared to C1q ≥ 11 mg/dl. Conclusion: C1q‐mediated HSC activation in liver fibrosis is associated with CTGF elevation. Additionally, serum C1q may be diagnostic for survival in human chronic liver diseases.
An Eye-Opening Case of Persistent Headaches and Fever in a Teenager
Altman, Marcus, Mullin, Rachael E., Felder, Kimberly, Vaz, Louise E. , Scruggs, Brittni A. , Scruggs, Brittni A , Mullin, Rachael , Starkey, Jay

Mayo Clinic

Clinical Pediatrics | October 6, 2022 | Volume: 62 | Issue: 5 | Pages: 492-497

10.1177/00099228221123828 | PMID 36199235 Get It

Patient Use of Physicians’ First (Given) Name in Direct Patient Electronic Messaging
Harvey, Jamison A. , Butterfield, Richard , Ochoa, Shari A. , Yang, Yul W.

Mayo Clinic

JAMA Network Open | October 5, 2022 | Volume: 5 | Issue: 10 | Pages: e2234880

10.1001/jamanetworkopen.2022.34880 | PMID 36197668 Get It

This cohort study examines factors that may contribute to whether patients address physicians differently through electronic messaging
A Novel Mutation in Lafora Disease and Update on Pathophysiology and Future Treatments
Nordli, Douglas R. , Rao, Chethan K. , Galán, Fernando , Galan, Fernando N , Nordli Iii, Douglas R , Delgado‐Escueta, Antonio V.

Mayo Clinic

Child Neurology Open | October 5, 2022 | Volume: 9 | Issue: No issue available | Pages: No page available

10.1177/2329048x221126361 | PMID 36211619 Get It

Lafora disease is a rare refractory epilepsy that results in death. This report highlights two cases of lafora disease and introduces a novel mutation in the patients. A review of the pathophysiology and future therapies is reviewed.
Heme Proteins and Kidney Injury: Beyond Rhabdomyolysis
Nath, Karl A. , Singh, Raman Deep , Croatt, Anthony J., Adams, Christopher M. , Adams, Christopher M

Mayo Clinic

Kidney360 | October 5, 2022 | Volume: 3 | Issue: 11 | Pages: 1969-1979

10.34067/kid.0005442022 | PMID 36514409 Get It

Heme proteins, the stuff of life, represent an ingenious biologic strategy that capitalizes on the biochemical versatility of heme, and yet is one that avoids the inherent risks to cellular vitality posed by unfettered and promiscuously reactive heme. Heme proteins, however, may be a double-edged sword because they can damage the kidney in certain settings. Although such injury is often viewed mainly within the context of rhabdomyolysis and the nephrotoxicity of myoglobin, an increasing literature now attests to the fact that involvement of heme proteins in renal injury ranges well beyond the confines of this single disease (and its analog, hemolysis); indeed, through the release of the defining heme motif, destabilization of intracellular heme proteins may be a common pathway for acute kidney injury, in general, and irrespective of the underlying insult. This brief review outlines current understanding regarding processes underlying such heme protein-induced acute kidney injury (AKI) and chronic kidney disease (CKD). Topics covered include, among others, the basis for renal injury after the exposure of the kidney to and its incorporation of myoglobin and hemoglobin; auto-oxidation of myoglobin and hemoglobin; destabilization of heme proteins and the release of heme; heme/iron/oxidant pathways of renal injury; generation of reactive oxygen species and reactive nitrogen species by NOX, iNOS, and myeloperoxidase; and the role of circulating cell-free hemoglobin in AKI and CKD. Also covered are the characteristics of the kidney that render this organ uniquely vulnerable to injury after myolysis and hemolysis, and pathobiologic effects emanating from free, labile heme. Mechanisms that defend against the toxicity of heme proteins are discussed, and the review concludes by outlining the therapeutic strategies that have arisen from current understanding of mechanisms of renal injury caused by heme proteins and how such mechanisms may be interrupted.
Limited activity of luspatercept in myelofibrosis and myeloid neoplasms other than myelodysplastic syndromes with ring sideroblasts
Gangat, Naseema , Chetram, Deandra , McCullough, Kristen , Al‐Kali, Aref , Begna, Kebede H. , Litzow, Mark R. , Foran, James M. , Badar, Talha , Palmer, Jeanne , Patnaik, Mrinal M. , Pardanani, Animesh , Tefferi, Ayalew , Begna, Kebede , Litzow, Mark R. , Badar, Talha , Patnaik, Mrinal , Pardanani, Animesh , Tefferi, Ayalew , McCullough, Kristen B , Hogan, William J.

Mayo Clinic

American Journal of Hematology | October 5, 2022 | Volume: 97 | Issue: 12 | Pages: No page available

10.1002/ajh.26749 | PMID 36197043 Get It

Racial Diversity and Reporting in United States Food and Drug Administration Registration Trials for Thoracic Malignancies from 2006 to 2020
Chiang, Ryan S. , Desai, Aakash , Glover, Michael , Hui, Gavin , Ramchandran, Kavitha , Wakelee, Heather A. , Khaki, Ali Raza , Khaki, Ali Raza , Desai, Aakash P , Ramchandran, Kavitha J , Lythgoe, Mark Peter

Mayo Clinic

Cancer Investigation | October 5, 2022 | Volume: 41 | Issue: 1 | Pages: 43-47

10.1080/07357907.2022.2131808 | PMID 36197034 Get It

Hepatobiliary and pancreatic resection for cholangiocarcinoma in patients with primary sclerosing cholangitis
Pery, Ron, Smoot, Rory L. , Nagorney, David M. , Smoot, Rory L , Thiels, Cornelius A. , Cleary, Sean P. , Vierkant, Robert A. , Ilyas, Sumera I. , Gores, Gregory J.

Mayo Clinic

British Journal of Surgery | October 5, 2022 | Volume: 109 | Issue: 11 | Pages: 1032-1035

10.1093/bjs/znac229 | PMID 35848775 Get It